RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting

Highlight

– Elevated plasma RIPK3 levels strongly predict multi-organ failure and mortality in patients with acute decompensation (AD) and acute-on-chronic liver failure (ACLF).
– RIPK3 outperforms other cell death markers in correlating with hepatic and renal dysfunction in cirrhosis exacerbations.
– A novel mortality prediction model incorporating RIPK3, CLIF-C Organ Failure score, and white blood cell count shows high diagnostic accuracy and external validation.
– Increased hepatic RIPK1 expression in ACLF supports the necroptotic pathway’s role in disease progression and mortality, enabling targeted therapeutic strategies.

Study Background